Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
GS-4774 combined with Viread stimulates immune activity against the virus.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Just over half of people who use drugs in eight cities are hepatitis C virus antibody positive.
Bulevirtide plus pegylated interferon shows promise for hard-to-treat coinfection.
Selonsertib did not improve liver fibrosis more than a placebo.
Fecal microbiota transplantation can help reverse brain impairment in people with liver failure.
Among HIV-positive people, mortality related to hepatitis B and C is falling but deaths due to NAFLD are rising.
People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.
Keytruda and Opdivo showed antitumor activity in some patients and acceptable side effects in real-world use.
People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.
Nearly a quarter of those taking a higher dose of Ocaliva saw an improvement in liver scarring.
The VA has cured HCV in nearly 100,000 veterans, which will dramatically reduce the development of advanced liver disease and liver cancer.
Use of cost-reducing strategies is still common, but has decreased since 2013.
Ned Sharpless has been appointed interim head of the regulatory agency after the unexpected resignation of the commissioner.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.